Sujith Samarasinghe
Overview
Explore the profile of Sujith Samarasinghe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1994
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lum S, Eikema D, Piepenbroek B, Wynn R, Samarasinghe S, Dalissier A, et al.
Blood
. 2024 Jul;
144(12):1329-1342.
PMID: 38968140
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only established curative option for Fanconi anemia (FA)-associated bone marrow failure (BMF)/aplastic anemia (AA) and acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS). We...
2.
Hodder A, Leiter S, Kennedy J, Addy D, Ahmed M, Ajithkumar T, et al.
Nat Med
. 2024 Jul;
30(7):1905-1912.
PMID: 38956197
Clinical whole-genome sequencing (WGS) has been shown to deliver potential benefits to children with cancer and to alter treatment in high-risk patient groups. It remains unknown whether offering WGS to...
3.
Oporto Espuelas M, Burridge S, Kirkwood A, Bonney D, Watts K, Shenton G, et al.
Blood Cancer J
. 2024 Apr;
14(1):66.
PMID: 38622139
CAR T-cell therapy has transformed relapsed/refractory (r/r) B-cell precursor acute lymphoblastic leukaemia (B-ALL) management and outcomes, but following CAR T infusion, interventions are often needed. In a UK multicentre study,...
4.
Wimalachandra M, Dissanayake R, Raj R, Kulasekeraraj A, Samarasinghe S, Gooneratne L
Hematology
. 2024 Apr;
29(1):2337160.
PMID: 38597819
Pathogenic variants in the genes ( and cause bone marrow failure with characteristic syndromic features. We report a case of a previously healthy, 3-year-old boy with no dysmorphology, who presented...
5.
Hodder A, Mishra A, Enshaei A, Baird S, Elbeshlawi I, Bonney D, et al.
J Clin Oncol
. 2023 Nov;
42(8):907-914.
PMID: 37967307
Purpose: We tested whether blinatumomab (Blina) is effective as a toxicity-sparing alternative to first-line intensive chemotherapy in children and young persons (CYP) with B-ALL who were chemotherapy-intolerant or chemotherapy-resistant. Methods:...
6.
OConnor D, Joy M, Enshaei A, Kirkwood A, Kearns P, Samarasinghe S, et al.
Blood Adv
. 2023 Oct;
7(23):7231-7234.
PMID: 37824845
No abstract available.
7.
Gabelli M, Oporto-Espuelas M, Burridge S, Chu J, Farish S, Hedges E, et al.
Blood Adv
. 2023 Oct;
8(8):1959-1963.
PMID: 37820111
No abstract available.
8.
Jackson T, Napper R, Haeusler G, Pizer B, Bate J, Grundy R, et al.
Arch Dis Child
. 2023 Jan;
108(3):192-197.
PMID: 36600323
Objective: To evaluate a new protocol of risk stratification and early discharge for children with febrile neutropenia (FN). Design: Prospective service evaluation from 17 April 2020 to 16 April 2021....
9.
Fordham N, Bartram J, Ghorashian S, OConnor D, Taylor A, Sibson K, et al.
Br J Haematol
. 2022 Aug;
199(3):447-451.
PMID: 35974444
No abstract available.
10.
Moorman A, Antony G, Wade R, Butler E, Enshaei A, Harrison C, et al.
J Clin Oncol
. 2022 Jun;
40(36):4228-4239.
PMID: 35714315
Purpose: The aim of the randomized trial, UKALL2003, was to adjust treatment intensity on the basis of minimal residual disease (MRD) stratification for children and young adults with acute lymphoblastic...